EPOCH trial design

Interventional Oncology

EPOCH Trial

 

An international, multi-centre, open-label, phase III, randomised controlled trial to study the impact of TheraSphere™ Y-90 Glass Microspheres in combination with second-line systemic chemotherapy for colorectal liver metastases (CLM)

 

Trial Design

Phase III, open label, multicentre (95 sites), prospective, 1:1 randomised trial.
Primary endpoints:

  • PFS according to RECIST 1.1 from time of randomization to disease progression or death 
  • hPFS according to RECIST 1.1, from time of randomization to thedate of disease progression in the liver or death ​


Sign in below and receive trial results in your inbox

 

Please accept cookie consent at the bottom of page to view the content

All the personal data provided herein will be stored and used by BSC in line with its Privacy Policy in order to provide you with the requested newsletter and materials. The termination of the subscription will generate their suppression (unless we have your contact detail for other motives).
 
Top